Table 1.
Timing of study assessment.
| Visit | Screening | Treatment (baseline) | Follow-up | Follow-up |
|---|---|---|---|---|
| Point of time | Between − 14 days and day 0 | day 0 | Month 1 | Month 3 |
| Assessment | ||||
| Inclusion/exclusion criteria | X | |||
| Informed consent | X | |||
| Demographic data | X | |||
| Medical history | X | |||
| Concurrent medications | X | |||
| Ophthalmic history | X | |||
| BCVA at 4 m prior to dilation | X | X | X | X |
| Slit lamp examination | X | X | X | X |
| Fundus examination | X | X | X | X |
| IOP measurement | X | X | X | X |
| Macular sensitivity by microperimetry | X | Xa | X | X |
| FAF by BAF | X | X | X | X |
| Structural SD-OCT | X | X | X | X |
| Subthreshold laser treatment | X | |||
| Adverse events assessment | X | X | X |
BCVA Best-corrected visual acuity, IOP intra-ocular pressure, FAF fundus autofluorescence, BAF blue autofluorescence, SD-OCT spectral-domain optical coherence tomography.
aIf not executed on screening visit.